Joel Mawdsley

Joel Mawdsley

Auto-generated profile, based on publicly available information

Joel Mawdsley

Guy’s and St Thomas’ NHS Foundation Trust, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2021 in Gut
Verified
Conference Paper
Open access
PDF file
MSMark A Samaan
Mark A Samaan
GCGeorgina Cunningham
Georgina Cunningham
GTGokul Tamilarasan
Gokul Tamilarasan
SRShuvra Ray
Shuvra Ray
JMJoel Mawdsley
Joel Mawdsley
PIPeter Irving
Peter Irving
Background Patient-reported outcomes (PRO) have an increasingly important role in IBD. This is true of monitoring of disease activity in clinical practice and as well as the evaluation of new therapies, when used as clinical trial endpoints. An interim two-item PRO (PRO2) has been developed for UC that ranges from 0–6 and consists of the patient derived items from the Mayo score (rectal bleeding and stool frequency). PRO2 was internally validated against endoscopic outcomes. We aimed to add external validation across a range of clinical, biochemical and quality of life outcomes. Methods Data was collected as part of the GO-­LEVEL study, an open-­label, phase IV, investigator-initiated study (NCT03124121) which included a prospective cohort of UC patients commencing golimumab induction therapy, as well as a cross­-sectional cohort receiving maintenance treatment. Patients commencing induction therapy all had disease activity objectively confirmed and were evaluated at weeks 6, 10 and 14. Patients receiving maintenance therapy were recruited either at the point of flare, or during stable remission. Clinical disease activity was evaluated using PRO2 and SCCAI, quality of life using IBD-Control as well as a 100 mm visual analogue scale (IBD-Control-VAS), and biochemical activity using FC and CRP. Clinical remission was defined as a score of <3 using SCCAI, or 0 using PRO2. Correlations were calculated using Spearman’s correlation coefficient (rs) and contingency table analyses using Chi square. Results GO-LEVEL included a total of 112 patients across the two study cohorts. A total of 217 PRO2 assessments were made with concurrent SCCAI and IBD-Control scores available at all timepoints. CRP measurements were available at 214 of these and FC at 207. Strong correlations were observed between PRO2 and SCCAI (rs=0.94, p<0.0001), as well as with IBD-Control (rs=-0.82, p<0.0001) and IBD-Control-VAS (rs=-0.78, p<0.0001). Significant correlations were also seen between PRO2 and FC (rs=0.38, p<0.0001) as well as PRO2 and CRP (rs=0.31, p<0.0001). Of the 217 assessments 109 were in SCCAI defined remission, 95 were in PRO2 defined remission and the two were highly contingent (p<0.0001). The sensitivity and specificity of disease activity assessments made with PRO2 vs SCCAI were 0.85 and 0.98, respectively. The positive and negative predictive values were 0.98 and 0.87, respectively. Scatter plots of PRO2 against SCCAI (left panel, rs=0.94, p<0.0001) and faecal calprotectin (right panel, rs=0.38, p<0.0001) Conclusions The PRO2 performs well when validated against an established clinical disease activity index (SCCAI), quality of life assessments and biochemical markers of disease activity. PRO2 assessments have the benefit of being more rapid to administer (comprising of only 2 items) than SCCAI (6 items), whilst providing similar and accurate evaluations of remission status.

1 January 2021 in Efficacy and Mechanism Evaluation
Verified
Journal Article
Open access
PDF file
AAAshish Awasthi
Ashish Awasthi
JBJamie Barbour
Jamie Barbour
ABAndrew D Beggs
Andrew D Beggs
PBPradeep Bhandari
Pradeep Bhandari
DBDaniel Blakeway
Daniel Blakeway
YWYvonne Wallis
Yvonne Wallis
Background: Chronic ulcerative colitis is a large bowel inflammatory condition associated with increased colorectal cancer risk over time, resulting in 1000 colectomies per year in the UK. Despite intensive colonoscopic surveillance, 50% of cases progress to invasive cancer before detection. Detecting early (precancer) molecular changes by analysing biopsies from routine colonoscopy should increase neoplasia detection. Objectives: To establish a deoxyribonucleic acid (DNA) marker panel associated with early neoplastic changes in ulcerative colitis patients. To develop the DNA methylation test for high-throughput analysis within the NHS. To prospectively evaluate the test within the existing colonoscopy surveillance programme. Design: Module 1 analysed 569 stored biopsies from neoplastic and non-neoplastic sites/patients using pyrosequencing for 11 genes that were previously reported to have altered promoter methylation associated with colitis-associated neoplasia. Classifiers were constructed to predict neoplasia based on gene combinations. Module 2 translated analysis to a NHS laboratory, assessing next-generation sequencing to increase speed and reduce cost. Module 3 applied the molecular classifiers within a prospective diagnostic accuracy study, in the existing ulcerative colitis surveillance programme. Comparisons were made between baseline and reference colonoscopies undertaken in a stratified patient sample 6–12 months later. Setting: Thirty-one UK hospitals. Participants: Patients with chronic ulcerative colitis, either for at least 10 years and extensive disease, or with primary sclerosing cholangitis. Interventions: An optimised DNA methylation classifier tested on routine mucosal biopsies taken during colonoscopy. Main outcome: Identifying ulcerative colitis patients with neoplasia. Results: Module 1 selected five genes with specificity for neoplasia. The optimism-adjusted area under the receiver operating characteristic curve for neoplasia was 0.83 (95% confidence interval 0.79 to 0.88). Precancerous neoplasia showed a higher area under the receiver operating characteristic curve of 0.88 (95% confidence interval 0.84 to 0.92). Background mucosa had poorer discrimination (optimism-adjusted area under the receiver operating characteristic curve was 0.68, 95% confidence interval 0.62 to 0.73). Module 2 was unable to develop a robust next-generation sequencing assay because of the low amplification rates across all genes. In module 3, 818 patients underwent a baseline colonoscopy. The methylation assay (testing non-neoplastic mucosa) was compared with pathology assessments for neoplasia and showed a diagnostic odds ratio of 2.37 (95% confidence interval 1.46 to 3.82; p = 0.0002). The probability of dysplasia increased from 11.1% before testing to 17.7% after testing (95% confidence interval 13.0% to 23.2%), with a positive methylation result suggesting added value in neoplasia detection. To determine added value above colonoscopy alone, a second (reference) colonoscopy was performed in 193 patients without neoplasia. Although the test showed an increased number of patients with neoplasia associated with primary methylation changes, this failed to reach statistical significance (diagnostic odds ratio 3.93; 95% confidence interval 0.82 to 24.75; p = 0.09). Limitations: Since the inception of ENDCaP-C, technology has advanced to allow whole-genome or methylome testing to be performed. Conclusions: Methylation testing for chronic ulcerative colitis patients cannot be recommended based on this study. However, following up this cohort will reveal further neoplastic changes, indicating whether or not this test may be identifying a population at risk of future neoplasia and informing future surveillance programmes. Trial registration: Current Controlled Trials ISRCTN81826545. Funding: This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research (NIHR) partnership, and will be published in full in Efficacy and Mechanism Evaluation; Vol. 8, No. 1. See the NIHR Journals Library website for further project information.

1 January 2022 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
AMA C Moore
A C Moore
DRD Russell
D Russell
RDRobin Dart
Robin Dart
SDS Dias
S Dias
SGS Ghuman
S Ghuman
MSMark A Samaan
Mark A Samaan
Biosimilars have delivered significant cost savings, increasing access to biologics for many patients. While numerous studies have demonstrated no difference in efficacy between originators and biosimilars, the impact of switching between originator and biosimilar adalimumab on drug levels and disease activity in real world cohorts remains largely unknown. We conducted a retrospective observational cohort study of, 392 patients with IBD (347 (89%) CD, 45 (11%) UC) who had switched from Humira to the biosimilar, Idacio, between February - November, 2021. Therapeutic drug monitoring was carried out using a commercially available, drug sensitive ELISA (LISA TRACKER, Theradiag). Therefore, antidrug antibodies could only be detected in the setting of low or absent serum drug concentrations. Drug level data was parametric and analysed by paired student t test and Pearson correlation coefficient. CRP data was analysed by Wilcoxon test. Data was analysed using GraphPad Prism. The baseline characteristics of the study participants are presented in the table., 96 patients had paired adalimumab drug levels before and after the switch. There was no difference between median adalimumab drug levels before and after the switch (9.5 vs, 9.2 ug/mL, p=0.67). Furthermore, drug levels were positively correlated before and after switching demonstrating similar levels at both time points for most patients (correlation co-efficient, 0.47, p <, 0.0001) (Figure, 1). Prior to switching, no patients had detectable antidrug antibodies. Following switch, one patient (1%) developed high-titre antidrug antibodies and undetectable drug levels. Prior to switch their levels were, 14, without detectable antidrug antibodies CRP levels were available for, 163 patients before and after the switch, with no difference in median CRP at either time point (1 vs, 1mg/L p=0.60). 33 (8%) patients experienced injection site pain with Idacio and therefore, switched back to Humira. The annual cost saving to the UK National Health Service for patients on weekly and every other week switched to Idacio is £5096 and £2548, respectively Our study demonstrates stable pharmacokinetics and biochemical disease activity amongst a significant cohort of patients switching from originator to biosimilar adalimumab as part of a real-world switching program. However, a small proportion of patients did not tolerate Idacio due to injection site pain. There are clear financial benefits in carrying out non-medical, biosimilar switching programs but further work is needed to evaluate the effect on clinical and endoscopic disease activity in a real-world setting.

16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
SHSailish Honap
Sailish Honap
ESEsha Sharma
Esha Sharma
SRShuvra Ray
Shuvra Ray
JMJoel Mawdsley
Joel Mawdsley
SASimon H. Anderson
Simon H. Anderson
PIPeter M. Irving
Peter M. Irving

16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
SHSailish Honap
Sailish Honap
ESEsha Sharma
Esha Sharma
SRShuvra Ray
Shuvra Ray
JMJoel Mawdsley
Joel Mawdsley
SASimon H. Anderson
Simon H. Anderson
PIPeter M. Irving
Peter M. Irving

16 June 2022 in Gastroenterology
Verified
Journal Article
Closed access
SMSusanna Meade
Susanna Meade
KPKamal V Patel
Kamal V Patel
RLRaphael P Luber
Raphael P Luber
DODearbhaile O'Hanlon
Dearbhaile O'Hanlon
ACAndra Caracostea
Andra Caracostea
PIPeter M. Irving
Peter M. Irving